Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps - SYNAPSE (StudY in NAsal Polyps Patients to Assess the Safety and Efficacy of Mepolizumab)

Trial Profile

A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps - SYNAPSE (StudY in NAsal Polyps Patients to Assess the Safety and Efficacy of Mepolizumab)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs Mepolizumab (Primary) ; Mometasone
  • Indications Nasal polyps
  • Focus Registrational; Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors GlaxoSmithKline Research & Development
  • Most Recent Events

    • 03 May 2018 Planned End Date changed from 2 Aug 2019 to 26 Dec 2019.
    • 03 May 2018 Planned primary completion date changed from 2 Aug 2019 to 26 Dec 2019.
    • 18 Jan 2018 Planned End Date changed from 20 Jun 2019 to 2 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top